Compare REPL & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REPL | PRCT |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2018 | 2021 |
| Metric | REPL | PRCT |
|---|---|---|
| Price | $10.82 | $17.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 15 |
| Target Price | $19.50 | ★ $22.25 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $28.32 |
| Revenue Next Year | $497.81 | $20.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $1.50 | $16.67 |
| 52 Week High | $16.33 | $38.11 |
| Indicator | REPL | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 32.47 | 45.00 |
| Support Level | $6.81 | $16.84 |
| Resistance Level | $11.05 | $29.27 |
| Average True Range (ATR) | 0.71 | 0.99 |
| MACD | -0.20 | 0.12 |
| Stochastic Oscillator | 1.83 | 35.14 |
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.